Gemcitabine Clinical Trials
211 recruitingDrug
Phase 2129Phase 359Phase 151Not Applicable5Phase 41Early Phase 11
Showing 1–20 of 211 trials
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Stage IV Nasopharyngeal Carcinoma AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8Stage II Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI)50 enrolled85 locationsNCT06064097
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled135 locationsNCT05139017
Recruiting
Phase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled88 locationsNCT06029270
Recruiting
Phase 2
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled134 locationsNCT06770582
Recruiting
Phase 1Phase 2
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
Margaret Gatti-Mays42 enrolled1 locationNCT06026657
Recruiting
Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
Solid Tumor
Astellas Pharma Inc681 enrolled62 locationsNCT05382559
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Breast Cancer
AstraZeneca625 enrolled321 locationsNCT06103864
Recruiting
Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche100 enrolled53 locationsNCT06806033
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled266 locationsNCT06841354
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC780 enrolled267 locationsNCT06312137
Recruiting
Phase 3
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled159 locationsNCT06524544
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Ovarian CancerPlatinum-sensitive Ovarian Cancer
Genmab688 enrolled2 locationsNCT07564141
Recruiting
Phase 2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NeoplasmsAdolescentChild
Eli Lilly and Company105 enrolled73 locationsNCT05999994
Recruiting
Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
BioNTech SE558 enrolled155 locationsNCT07173751
Recruiting
Phase 1Phase 2
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Metastatic Biliary Tract Cancer
M.D. Anderson Cancer Center50 enrolled1 locationNCT06548412
Recruiting
Phase 1Phase 2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC460 enrolled28 locationsNCT06843447
Recruiting
Phase 2
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Resectable Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital40 enrolled1 locationNCT05640791
Recruiting
Phase 3
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Ovarian Neoplasms
GlaxoSmithKline450 enrolled5 locationsNCT07286266